Back to Rheumatology
Rheumatologyv2016Evidence-Based

Hydroxychloroquine (Plaquenil) Dosing Calculator

Calculates maximum daily hydroxychloroquine dose to reduce retinopathy risk. Uses actual body weight to determine safe dosing limits based on 2016 American Academy of Ophthalmology guidelines recommending ≤5 mg/kg/day to minimize retinal toxicity.

Clinical Input Parameters

kg
Range: 20 — 300 kg
Clinical Assessment
Awaiting Parameters
max daily dose
—mg
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Hydroxychloroquine (Plaquenil) Dosing Calculator is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within rheumatology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Maximum daily dose (mg) = actual body weight (kg) × 5 mg/kg. Consider dose reduction if risk factors present or for long-term use (>5 years).

Clinical Pearls & Practice Notes

  • 2016 AAO guidelines reduced maximum dose from 6.5 mg/kg to 5 mg/kg based on retinopathy evidence
  • Actual body weight preferred over ideal body weight for dose calculation
  • Doses >5 mg/kg actual weight significantly increase retinopathy risk
  • 10-year retinopathy risk: 2% (≤5 mg/kg) vs 10% (>5 mg/kg)
  • 20-year retinopathy risk: 20% (≤5 mg/kg) vs 40% (>5 mg/kg)
  • Risk factors: age >65, renal disease, liver disease, previous retinal disease
  • Baseline ophthalmologic exam recommended before starting therapy
  • Annual screening recommended after 5 years of use (earlier if risk factors)
  • Consider dose reduction for patients with risk factors even if within weight limits
  • Cumulative dose and duration of therapy also contribute to retinopathy risk
  • Retinopathy may progress even after drug discontinuation

Evidence & Literature Citations

  1. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016 Jun;123(6):1386-94.
  2. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014 Dec;132(12):1453-60.
  3. Jorge AM, Melles RB, Zhang Y, Lu N, Rai SK, Young LH, Choi HK. Hydroxychloroquine retinopathy--implications of research advances for rheumatology care. Nat Rev Rheumatol. 2018 Dec;14(12):693-703.

Score Interpretation Ranges

Low Dose0 – 200 pts

≤200 mg daily

Standard Dose201 – 400 pts

201-400 mg daily

High Dose401 – 600 pts

>400 mg daily

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.